Glenmede Trust’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $280K | Sell |
1,660
-76,917
| -98% | -$11.4M | ﹤0.01% | 1212 |
|
|
2026
Q1 | $10.4M | Sell |
78,577
-3,124
| -4% | -$415K | 0.05% | 320 |
|
|
2025
Q4 | $11.6M | Buy |
+81,701
| New | +$11.8M | 0.05% | 301 |
|
|
2025
Q1 | $17.1M | Sell |
154,827
-8,529
| -5% | -$1.08M | 0.09% | 206 |
|
|
2024
Q4 | $22.3M | Buy |
163,356
+153,095
| +1,492% | +$18.9M | 0.11% | 169 |
|
|
2024
Q3 | $1.18M | Sell |
10,261
-828
| -7% | -$114K | 0.01% | 676 |
|
|
2024
Q2 | $1.53M | Sell |
11,089
-1,862
| -14% | -$255K | 0.01% | 612 |
|
|
2024
Q1 | $1.79M | Sell |
12,951
-202
| -2% | -$27.6K | 0.01% | 593 |
|
|
2023
Q4 | $1.73M | Buy |
13,153
+10,127
| +335% | +$1.17M | 0.01% | 577 |
|
|
2023
Q3 | $340K | Sell |
3,026
-6,238
| -67% | -$657K | ﹤0.01% | 951 |
|
|
2023
Q2 | $938K | Hold |
9,264
| – | – | 0.01% | 673 |
|
|
2023
Q1 | $938K | Sell |
9,264
-7,559
| -45% | -$787K | 0.01% | 675 |
|
|
2022
Q4 | $2.01M | Buy |
16,823
+6,525
| +63% | +$764K | 0.01% | 519 |
|
|
2022
Q3 | $1.09M | Sell |
10,298
-4,765
| -32% | -$483K | 0.01% | 632 |
|
|
2022
Q2 | $1.47M | Sell |
15,063
-1,750
| -10% | -$162K | 0.01% | 584 |
|
|
2022
Q1 | $1.58M | Sell |
16,813
-4,800
| -22% | -$407K | 0.01% | 597 |
|
|
2021
Q4 | $1.84M | Sell |
21,613
-10,269
| -32% | -$945K | 0.01% | 591 |
|
|
2021
Q3 | $3.06M | Sell |
31,882
-3,451
| -10% | -$326K | 0.02% | 471 |
|
|
2021
Q2 | $3.44M | Sell |
35,333
-529
| -1% | -$50.7K | 0.02% | 447 |
|
|
2021
Q1 | $3.49M | Sell |
35,862
-4,734
| -12% | -$496K | 0.02% | 441 |
|
|
2020
Q4 | $3.89M | Buy |
40,596
+17,363
| +75% | +$1.68M | 0.02% | 426 |
|
|
2020
Q3 | $2.23M | Sell |
23,233
-3,000
| -11% | -$347K | 0.01% | 479 |
|
|
2020
Q2 | $3.2M | Buy |
26,233
+6,971
| +36% | +$770K | 0.02% | 428 |
|
|
2020
Q1 | $2.07M | Hold |
19,262
| – | – | 0.01% | 619 |
|
|
2019
Q4 | $2.07M | Buy |
19,262
+1,066
| +6% | +$112K | 0.01% | 619 |
|
|
2019
Q3 | $1.64M | Buy |
18,196
+8,884
| +95% | +$830K | 0.01% | 649 |
|
|
2019
Q2 | $786K | Sell |
9,312
-10
| -0.1% | -$821 | ﹤0.01% | 802 |
|
|
2019
Q1 | $821K | Sell |
9,322
-10
| -0.1% | -$836 | ﹤0.01% | 782 |
|
|
2018
Q4 | $666K | Buy |
9,332
+112
| +1% | +$10.7K | ﹤0.01% | 801 |
|
|
2018
Q3 | $1.13M | Sell |
9,220
-8
| -0.1% | -$908 | ﹤0.01% | 733 |
|
|
2018
Q2 | $907K | Sell |
9,228
-1,280
| -12% | -$115K | ﹤0.01% | 726 |
|
|
2018
Q1 | $815K | Hold |
10,508
| – | – | ﹤0.01% | 816 |
|
|
2017
Q4 | $815K | Hold |
10,508
| – | – | ﹤0.01% | 816 |
|
|
2017
Q3 | $643K | Buy |
10,508
+9,908
| +1,651% | +$523K | ﹤0.01% | 854 |
|
|
2017
Q2 | $25K | Hold |
600
| – | – | ﹤0.01% | 1847 |
|
|
2017
Q1 | $25K | Buy |
+600
| New | +$25.7K | ﹤0.01% | 1847 |
|
|
2016
Q3 | – | Sell |
-41
| Closed | -$1K | – | 2645 |
|
|
2016
Q2 | $1K | Hold |
41
| – | – | ﹤0.01% | 2474 |
|
|
2016
Q1 | $1K | Sell |
41
-79
| -66% | -$3.13K | ﹤0.01% | 2517 |
|
|
2015
Q4 | $6K | Buy |
+120
| New | +$6.1K | ﹤0.01% | 2216 |
|
Other funds holding NBIX
Glenmede Trust's NBIX Position: Q2 2026 in Review
Glenmede Trust reduced its Neurocrine Biosciences (NBIX) stake by 98% in Q2 2026, selling an estimated $11.4M and leaving 1,660 shares worth $280K. The position accounts for ﹤0.01% of the portfolio, ranked #1212.
Glenmede Trust first reported a position in NBIX in Q4 2015 and has held it in 39 quarters since. The position peaked at $22.3M in Q4 2024. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Glenmede Trust held 1,660 shares of Neurocrine Biosciences worth $280K as of Q2 2026.
- Glenmede Trust sold 76,917 Neurocrine Biosciences shares in Q2 2026, an estimated $11.4M.
- Neurocrine Biosciences made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #1212 holding.
- Glenmede Trust first reported a position in Neurocrine Biosciences in Q4 2015 and has held it in 39 quarters since.
- Glenmede Trust's Neurocrine Biosciences position peaked at $22.3M in Q4 2024.
- 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.